November roundup

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Mitchell Fraser-Jones 4 December 2018 Est. reading: 6 min read

November Roundup

Mitchell Fraser-Jones
4 December 2018

“Real wage growth will lead to better consumer spending, improved affordability in the housing market and, of course, better Government tax receipts. I expect to see more falls in food price inflation which, when combined with lower oil prices (witness, the recent 30% fall in crude prices), will mean that inflation will fall further and faster than consensus has forecast. All very encouraging for the remainder of this year and as we look into 2019.”​

— Neil Woodford

After October’s steep declines, November marked a month of consolidation for most regional equity markets. Emerging markets rallied following a prolonged period of pressure, and similarly, a late-month recovery for technology stocks helped the US indices to finish in positive territory. In Europe, most major markets were marginally lower, and, in the UK, politics remained more important than economics as a key driver of sentiment.

The Bigger picture

The global macroeconomic picture continues to evolve pretty much along the lines we have been expecting. We have seen more disappointing economic data from the eurozone and, in a further challenge to the consensus view, an abrupt fall in the oil price, which is now down more than 30% in less than two months.

Elsewhere, there was more worrying data from the Chinese housing market and the latest survey data suggests that China’s economy remains under pressure.

Closer to home, the Brexit deal has been agreed with the European Union and Theresa May now has the next couple of weeks to go to the country and sell her deal, and for the business community to get behind it too.

The UK economy continues to perform well, with better-than-expected wage growth and lower-than-forecast inflation data. This means even stronger real wage growth, which will lead to better consumer spending, improved affordability in the housing market and, of course, better Government tax receipts. This is all very encouraging for the remainder of this year and as we look into 2019.

Read more of our latest ‘Bigger picture’ thoughts here

Woodford Funds: November roundup THE MONTH IN NUMBERS Value (per share) of Boston Scientific's agreed bid for BTG, a 37% premium to the prior day's closing share price, valuing the company at £3.3bn Decline in price per barrel of Brent crude oil since 3 October 2018 Annual rate of UK CPI in October 2018 (vs 2.5% forecast) Value of Immunocore's collaboration with Genentech Taylor Wimpey's dividend commitment in 2019 – equates to a yield of 13.7% Amount raised in Ultrahaptics' latest, oversubscribed financing round, to support the company's global expansion German GDP contracted in Q3 2018 3-month average annual UK pay growth, excluding bonuses (vs 3.1% forecast) Source: Bloomberg, Woodford. Past performance cannot be relied upon as a guide to future performance. THE MONTH IN NUMBERS 840p -32% 2.4% $100m £600m £35m -0.2% 3.2% Value (per share) of Boston Scientific's agreed bid for BTG, a 37% premium to the prior day's closing share price, valuing the company at £3.3bn Decline in price per barrel of Brent crude oil since 3 October 2018 Annual rate of UK CPI in October 2018 (vs 2.5% forecast) Value of Immunocore's collaboration with Genentech Taylor Wimpey's dividend commitment in 2019 – equates to a yield of 13.7% Amount raised in Ultrahaptics' latest, oversubscribed financing round, to support the company's global expansion German GDP contracted in Q3 2018 3-month average annual UK pay growth, excluding bonuses (vs 3.1% forecast) Source: Bloomberg, Woodford. Past performance cannot be relied upon as a guide to future performance.

Patient Capital

In November, as well as the Autolus news mentioned above, we saw positive news from a number of other holdings in the Woodford Patient Capital Trust portfolio.

Four significant milestones

Immunocore announced a $100m collaboration with Genentech, a member of the Roche Group.

Mission Therapeutics links with global pharmaceutical company AbbVie to develop Alzheimer’s, Parkinson’s therapies.

Spin Memory raises $52m and enters into commercial agreement with Arm, the world’s leading semiconductor intellectual property company.

Ultrahaptics raises £35m to cement its place as a global leader in virtual technology.

Conclusion

As we head towards 2019, we are confident that the individual constituent parts of the UK economy will continue to deal with the prospect of Brexit in the same way that they have been doing since the referendum in June 2016.

Our UK thesis continues to be based around more people in work, with faster real wage growth, more spending from Government, a pick-up in investment and benign credit conditions. Banks will continue to grow lending and, in particular, the growth in the housing market will continue with more housing transactions, more mortgage approvals (for house purchase rather than buy-to-let) and gently rising prices. Monetary policy should remain supportive, with low interest rates, because inflation will continue to fall.

Outside of the UK, China’s growth challenges will become increasingly obvious and the economy’s growth rate will fall further, emerging market economies will continue to battle with the issues that have troubled them in the second half of 2018, and Europe’s growth slowdown will continue. The new dynamic in the global outlook will, we believe, be a lower contribution to global growth from the US. Here, the effects of Trump’s fiscal stimulus will subside and the monetary policy response (higher interest rates and quantitative tightening) will have an increasingly deleterious impact on growth.

As ever, our focus remains on the long-term and, from that perspective, we continue to believe that the Woodford investment strategy is very appropriate for this environment.

Register for updates

Register now to receive roundup alerts by email.

What are the risks?

  • The value of investments and any income from them may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The annual management charge applicable to the funds is charged to capital, so the income of the funds may be higher but capital growth may be restricted or capital may be eroded
  • The funds may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits
  • The funds may invest in overseas securities and be exposed to currencies other than pound sterling
  • The LF Woodford Income Focus Fund will be invested in a concentrated portfolio of securities – the fund is not restricted by reference to any geographical region, sector or market capitalisation
  • The LF Woodford Equity Income Fund may invest in unquoted securities, which may be less liquid and more difficult to realise than publicly traded securities

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund – or Key Information Document (KID) for the trust – and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

You should note that capital is at risk with these investments and you may get back less than you invested. The value of the fund or trust as well as any income paid will fluctuate which may partly be the result of exchange rate changes.

The price of shares in the Woodford Patient Capital Trust is determined by market supply and demand, and this may be different to the net asset value of the trust.

The Woodford Patient Capital Trust currently intends to conduct its affairs so that its securities can be recommended by IFAs to ordinary retail investors in accordance with the FCA’s rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The securities are excluded from the FCA’s restrictions which apply to non-mainstream investment products because they are shares in an investment trust.

Young businesses have a different risk profile to mature blue-chip companies – risks are much more stock-specific, which implies a lower correlation with equity markets and the wider economy. Long-term outcomes are more binary – extremely attractive rewards for success but some businesses will inevitably fail to fulfil their potential and this may expose Woodford Patient Capital Trust investors to the risk of capital losses. As it can take years for young businesses to fulfil their potential, this investment requires patience.

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address 9400 Garsington Road, Oxford OX4 2HN.

Woodford Patient Capital Trust plc is incorporated in England and Wales, company number 09405653. Registered as an investment company under section 833 of the Companies Act 2006. Registered address Beaufort House, 51 New North Road, Exeter, EX4 4EP.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland. The Fund’s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at www.fundinfo.com.

© 2018 Woodford Investment Management Ltd.
All rights reserved.

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.

Privacy Preference Center

Experience Tracking

Lets our analytics service track you across our different websites and enables data sharing among our different marketing tools.

AMCV_[Tracker ID]@AdobeOrg (Adobe), [Tracker ID]@AdobeOrg (Adobe)
Adobe Analytics (helps us provide you with more relevant experiences and content based on your likely interests). Cookies: demdex, dextp, dpm, DST, DSTJS
Twitter personalisation (by better understanding how devices are related, Twitter can use information from one device to help personalize the Twitter experience on another device). Cookies: personalization_id
Heap Analytics (provides metrics on user behaviour and actions throughout the site). Cookies: _gid, _hp2_id.[Tracker ID],_hp2_props.[Tracker ID], _ga, _mkto_trk, optimizelyBuckets, optimizelyEndUserId, optimizelySegments, raygun4js-userid, _attribution_referrer, _csrf
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: _tmae ,ev_sync_dd,ev_sync_yh,everest_g_v2,gglck

Traffic Metrics

Allows Woodford to aggregate information on website usage and popular content

_ga, _gid
Google Analytics (tracks and reports website traffic and user behaviour): Cookie: CONSENT
New Relic (application and server performance monitoring – allows us to spot problems with our website code and improve them to keep things running smoothly). Cookie: JSESSIONID
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: __qca,__smToken, _ga, _mkto_trk, _rtbmedia

Search History

Populates the 'recent searches' section of the website navigation.

wf__recent_searches_untracked

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?